P14AS upregulates gene expression in the CDKN2A/2B locus through competitive binding to PcG protein CBX7

被引:4
|
作者
Li, Zhuoqi [1 ]
Qiao, Juanli [1 ]
Ma, Wanru [1 ]
Zhou, Jing [1 ]
Gu, Liankun [1 ]
Deng, Dajun [1 ]
Zhang, Baozhen [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Div Etiol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
lncRNA; P14AS; CBX7; p16(INK4A); p14(ARF); p15(INK4B); TUMOR-SUPPRESSOR; NONCODING RNA; POLYCOMB CBX7; CANCER; P16(INK4A); ANRIL;
D O I
10.3389/fcell.2022.993525
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: It is well known that P16 ( INK4A ), P14 ( ARF ), P15 ( INK4B ) mRNAs, and ANRIL lncRNA are transcribed from the CDKN2A/2B locus. LncRNA P14AS is a lncRNA transcribed from antisense strand of P14 ( ARF ) promoter to intron-1. Our previous study showed that P14AS could upregulate the expression level of ANRIL and P16 ( INK4A ) and promote the proliferation of cancer cells. Because polycomb group protein CBX7 could repress P16 ( INK4A ) expression and bind ANRIL, we wonder whether the P14AS-upregulated ANRIL and P16 ( INK4A ) expression is mediated with CBX7. Results: In this study, we found that the upregulation of P16 ( INK4A ), P14 ( ARF ), P15 ( INK4B ) and ANRIL expression was induced by P14AS overexpression only in HEK293T and HCT116 cells with active endogenous CBX7 expression, but not in MGC803 and HepG2 cells with weak CBX7 expression. Further studies showed that the stable shRNA-knockdown of CBX7 expression abolished the P14AS-induced upregulation of these P14AS target genes in HEK293T and HCT116 cells whereas enforced CBX7 overexpression enabled P14AS to upregulate expression of these target genes in MGC803 and HepG2 cells. Moreover, a significant association between the expression levels of P14AS and its target genes were observed only in human colon cancer tissue samples with high level of CBX7 expression (n = 38, p < 0.05), but not in samples (n = 37) with low level of CBX7 expression, nor in paired surgical margin tissues. In addition, the results of RNA immunoprecipitation (RIP)- and chromatin immunoprecipitation (ChIP)-PCR analyses revealed that lncRNA P14AS could competitively bind to CBX7 protein which prevented the bindings of CBX7 to both lncRNA ANRIL and the promoters of P16 ( INK4A ), P14 ( ARF ) and P15 ( INK4B ) genes. The amounts of repressive histone modification H3K9m3 was also significantly decreased at the promoters of these genes by P14AS in CBX7 actively expressing cells. Conclusions: CBX7 expression is essential for P14AS to upregulate the expression of P16 ( INK4A ), P14 ( ARF ), P15 ( INK4B ) and ANRIL genes in the CDKN2A/2Blocus. P14AS may upregulate these genes' expression through competitively blocking CBX7-binding to ANRIL lncRNA and target gene promoters.
引用
收藏
页数:12
相关论文
共 38 条
  • [1] P14AS upregulates gene expression in the CDKN2A/2B locus through competitive binding to PcG protein CBX7(vol 10, 1062931, 2022)
    Li, Zhuoqi
    Qiao, Juanli
    Ma, Wanru
    Zhou, Jing
    Gu, Liankun
    Deng, Dajun
    Zhang, Baozhen
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [2] Expression of ANRIL "Polycomb Complexes" CDKN2A/B/ARF genes in breast tumours: Identification of a two-gene (EZH2/CBX7) signature with independent prognostic value
    Meseure, D.
    Vacher, S.
    Alsibai, K. Drak
    Nicolas, A.
    Chemlali, W.
    Pasmant, E.
    Callens, C.
    Bieche, I.
    VIRCHOWS ARCHIV, 2017, 471 : S65 - S65
  • [3] Chromosome 9p21.3 effect on CDKN2A/2B expression in human coronary atherosclerosis
    Notarangelo, F.
    Marziliano, N.
    Foco, L.
    Giacalone, R.
    Tardio, C.
    Coppini, L.
    Bontardelli, F.
    Berzuini, C.
    Merlini, P. A.
    Ardissino, D.
    EUROPEAN HEART JOURNAL, 2012, 33 : 873 - 873
  • [4] Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B
    Congrains, Ada
    Kamide, Kei
    Oguro, Ryousuke
    Yasuda, Osamu
    Miyata, Keishi
    Yamamoto, Eiichiro
    Kawai, Tatsuo
    Kusunoki, Hiroshi
    Yamamoto, Hiroko
    Takeya, Yasushi
    Yamamoto, Koichi
    Onishi, Miyuki
    Sugimoto, Ken
    Katsuya, Tomohiro
    Awata, Nobuhisa
    Ikebe, Kazunori
    Gondo, Yasuyuki
    Oike, Yuichi
    Ohishi, Mitsuru
    Rakugi, Hiromi
    ATHEROSCLEROSIS, 2012, 220 (02) : 449 - 455
  • [5] Functional evidence for a role of combined CDKN2A (p16-p14ARF)/CDKN2B (p15) gene inactivation in malignant gliomas
    Simon, M
    Köster, G
    Menon, AG
    Schramm, J
    ACTA NEUROPATHOLOGICA, 1999, 98 (05) : 444 - 452
  • [6] Functional evidence for a role of combined CDKN2A (p16-p14ARF)/CDKN2B (p15) gene inactivation in malignant gliomas
    M. Simon
    Gertraud Köster
    Anil G. Menon
    Johannes Schramm
    Acta Neuropathologica, 1999, 98 : 444 - 452
  • [7] Expression of ANRIL-Polycomb Complexes-CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-Gene (EZH2/CBX7) Signature with Independent Prognostic Value
    Meseure, Didier
    Vacher, Sophie
    Alsibai, Kinan Drak
    Nicolas, Andre
    Chemlali, Walid
    Caly, Martial
    Lidereau, Rosette
    Pasmant, Eric
    Callens, Celine
    Bieche, Ivan
    MOLECULAR CANCER RESEARCH, 2016, 14 (07) : 623 - 633
  • [8] CDKN2A/B T2D GWAS Risk-SNPs Impact Locus Gene Expression and Proliferation in Human Islets
    Kong, Yahui
    Ly, Socheata
    Sharma, Rohit B.
    Stamateris, Rachel E.
    Alonso, Laura C.
    DIABETES, 2017, 66 : A6 - A6
  • [9] Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes
    Martinez-Hervas, Sergio
    Sanchez-Garcia, Veronica
    Herrero-Cervera, Andrea
    Vinue, Angela
    Tomas Real, Jose
    Ascaso, Juan F.
    Jane Burks, Deborah
    Gonzalez-Navarro, Herminia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [10] Type 1 diabetic mellitus patients with increased atherosclerosis risk display decreased CDKN2A/2B/2BAS gene expression in leukocytes
    Sergio Martínez-Hervás
    Verónica Sánchez-García
    Andrea Herrero-Cervera
    Ángela Vinué
    José Tomás Real
    Juan F. Ascaso
    Deborah Jane Burks
    Herminia González-Navarro
    Journal of Translational Medicine, 17